Delia Mezzanzanica

List of Publications by Year
in descending order

101 papers	3,903 citations	117453 34 h-index	133063 59 g-index
102 all docs	102 docs citations	102 times ranked	5897 citing authors

#	Article	IF	Citations
1	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. European Journal of Cancer, 2022, 161, 55-63.	1.3	3
2	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecological Cancer, 2022, 32, 799-803.	1.2	2
3	Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 5.	3.5	9
4	Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers, 2021, 13, 1544.	1.7	4
5	Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 246-258.	2.0	20
6	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells, 2020, 9, 903.	1.8	8
7	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. Journal of Gynecologic Oncology, 2020, 31, e92.	1.0	20
8	High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. OncoImmunology, 2019, 8, e1614856.	2.1	25
9	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Frontiers in Immunology, 2019, 10, 2514.	2.2	7
10	Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. Genes, 2019, 10, 678.	1.0	8
11	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	1.8	6
12	A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling. Cancers, 2019, 11, 255.	1.7	9
13	Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. NMR in Biomedicine, 2019, 32, e4016.	1.6	7
14	One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2092.	1.8	27
15	Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. Journal of Experimental and Clinical Cancer Research, 2018, 37, 146.	3.5	25
16	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	2.6	17
17	CDK6 protects epithelial ovarian cancer from platinumâ€induced death via FOXO3 regulation. EMBO Molecular Medicine, 2017, 9, 1415-1433.	3.3	61
18	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical Pharmacology, 2017, 144, 52-62.	2.0	11

#	Article	IF	Citations
19	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget, 2017, 8, 10919-10930.	0.8	17
20	Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation andin vivotumor growth in a highly tumorigenic ovarian cancer model. Oncotarget, 2017, 8, 55022-55038.	0.8	11
21	miRNA-based signature for predicting epithelial ovarian cancer recurrence. Translational Cancer Research, 2017, 6, S232-S234.	0.4	1
22	Choline Metabolism Alteration: A Focus on Ovarian Cancer. Frontiers in Oncology, 2016, 6, 153.	1.3	40
23	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	1.3	8
24	Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. Frontiers in Oncology, 2016, 6, 244.	1.3	15
25	Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 1387.	1.8	18
26	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	5.1	97
27	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	0.8	15
28	A miRNA signature assessing ovarian cancer prognosis. Oncoscience, 2016, 3, 308-310.	0.9	2
29	Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer, 2015, 34, 28-40.	4.9	26
30	Ovarian cancer: a molecularly insidious disease. Chinese Journal of Cancer, 2015, 34, 1-3.	4.9	34
31	IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget, 2015, 6, 43267-43280.	0.8	115
32	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal of the National Cancer Institute, 2015, 107, .	3.0	102
33	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical and Experimental Metastasis, 2015, 32, 29-38.	1.7	51
34	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunology Letters, 2015, 168, 105-110.	1.1	11
35	<scp>MiR</scp>â€506 inhibits multiple targets in the epithelialâ€toâ€mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. Journal of Pathology, 2015, 235, 25-36.	2.1	94
36	Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget, 2015, 6, 11216-11230.	0.8	20

#	Article	IF	Citations
37	Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. British Journal of Cancer, 2014, 110, 625-635.	2.9	24
38	Epigenetic Control of Autophagy by MicroRNAs in Ovarian Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	26
39	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	3.3	3
40	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). International Journal of Gynecological Cancer, 2014, 24, S5-S8.	1.2	74
41	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. International Journal of Gynecological Cancer, 2014, 24, S42-S47.	1.2	74
42	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer, 2014, 24, S20-S25.	1.2	116
43	Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. British Journal of Cancer, 2014, 110, 330-340.	2.9	45
44	MiR-506: A Multitasker in Suppression of the Epithelial-to-Mesenchymal Transition. RNA & Disease (Houston, Tex), 2014, 1, e447.	1.0	5
45	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	3.3	49
46	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncology, 2013, 9, 527-539.	1.1	35
47	Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. International Journal of Cancer, 2013, 132, 2597-2605.	2.3	39
48	Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma. BioMed Research International, 2013, 2013, 1-7.	0.9	43
49	The IL-18 Antagonist IL-18â€“Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment. Clinical Cancer Research, 2013, 19, 4611-4620.	3.2	40
50	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849.	1.1	21
51	Genomic Landscape of Ovarian Cancer. , 2013, , 295-348.		0
52	Characterisation of in vivo ovarian cancer models by quantitative ¹H magnetic resonance spectroscopy and diffusionâ€weighted imaging. NMR in Biomedicine, 2012, 25, 632-642.	1.6	30
53	miRNA control of apoptotic programs: focus on ovarian cancer. Expert Review of Molecular Diagnostics, 2011, 11, 277-286.	1.5	18
54	Interleukin (IL)â€18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. International Journal of Cancer, 2011, 129, 1116-1125.	2.3	25

#	Article	IF	Citations
55	Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget, 2011, 2, 1265-1278.	0.8	61
56	Aberrant phosphatidylcholine metabolism in human ovarian cancer. Chemistry and Physics of Lipids, 2010, 163, S63.	1.5	0
57	Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells. Cancer Research, 2010, 70, 2126-2135.	0.4	196
58	Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer. International Journal of Biochemistry and Cell Biology, 2010, 42, 210-213.	1.2	129
59	Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. International Journal of Biochemistry and Cell Biology, 2010, 42, 1262-1272.	1.2	63
60	c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocrine-Related Cancer, 2009, 16, 443-453.	1.6	19
61	Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients. Clinical Cancer Research, 2008, 14, 1726-1733.	3.2	83
62	Phosphatidylcholine-Specific Phospholipase C Activation in Epithelial Ovarian Cancer Cells. Cancer Research, 2008, 68, 6541-6549.	0.4	86
63	Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Molecular Cancer Therapeutics, 2007, 6, 762-772.	1.9	21
64	The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells. Molecular Cancer Research, 2007, 5, 1246-1253.	1.5	95
65	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. Journal of Immunotherapy, 2007, 30, 684-693.	1.2	70
66	M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 1920-1926.	2.3	78
67	Complement Activated by Chimeric Antiâ€"Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. Cancer Research, 2006, 66, 3876-3883.	0.4	36
68	Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. Journal of Gene Medicine, 2005, 7, 158-170.	1.4	26
69	Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression. Cancer Research, 2005, 65, 9369-9376.	0.4	258
70	CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 5202-5214.	3.2	52
71	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	2.6	75
72	A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene, 2004, 23, 7552-7560.	2.6	25

#	Article	IF	Citations
73	Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy, 2003, 10, 1018-1025.	2.3	68
74	UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene, 2003, 22, 4586-4593.	2.6	23
75	Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model. American Journal of Pathology, 2002, 160, 113-122.	1.9	11
76	Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: Evidence for defective processing in tumor cells. International Journal of Cancer, 2002, 98, 873-878.	2.3	42
77	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. Cytokine, 2001, 15, 27-38.	1.4	32
78	Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2. Cancer Immunology, Immunotherapy, 2001, 49, 679-686.	2.0	7
79	Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1. Cancer Immunology, Immunotherapy, 2000, 49, 296-304.	2.0	7
80	Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunology, Immunotherapy, 1997, 44, 257-264.	2.0	18
81	Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunology, Immunotherapy, 1997, 45, 187-189.	2.0	6
82	Unidirectional potentiation of binding between two anti-FBP MAbs: Evaluation of involved mechanisms. Journal of Cellular Biochemistry, 1995, 58, 47-55.	1.2	0
83	Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions. Stem Cells and Development, 1995, 4, 423-427.	1.0	42
84	Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. International Journal of Cancer, 1993, 55, 128-136.	2.3	10
85	Targeting of T lymphocytes against egf-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for t-cell activation. International Journal of Cancer, 1993, 55, 931-937.	2.3	15
86	A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate. Cancer Immunology, Immunotherapy, 1993, 37, 54-60.	2.0	10
87	Targeting of Anti-Tumor Responses with Bispecific Antibodies. Immunobiology, 1992, 185, 390-402.	0.8	17
88	Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. International Journal of Clinical and Laboratory Research, 1992, 22, 17-20.	1.0	6
89	Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. International Journal of Clinical and Laboratory Research, 1992, 21, 159-164.	1.0	13
90	Cytokine Release by Peripheral Blood Lymphocytes Targeted with Bispecific Antibodies, and Its Role in Blocking Tumor Growth. Annals of the New York Academy of Sciences, 1991, 636, 288-294.	1.8	6

#	Article	IF	Citations
91	Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization. International Journal of Cancer, 1991, 48, 284-290.	2.3	20
92	The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells. FEBS Journal, 1989, 178, 795-802.	0.2	38
93	Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. International Journal of Cancer, 1988, 41, 18-21.	2.3	17
94	Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. International Journal of Cancer, 1988, 42, 455-459.	2.3	41
95	Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB. Cancer Immunology, Immunotherapy, 1988, 26, 114-20.	2.0	33
96	Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components. International Journal of Cancer, 1988, 41, 609-615.	2.3	70
97	The Effect of Human Serum on the Binding Activity of Radiolabelled Monoclonal Antibodies. Tumori, 1987, 73, 547-554.	0.6	0
98	Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. Cancer Immunology, Immunotherapy, 1987, 24, 13-8.	2.0	16
99	Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. International Journal of Cancer, 1987, 39, 297-303.	2.3	284
100	Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups. Hybridoma, 1986, 5, 1-8.	0.9	32
101	Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. Frontiers in Oncology, 0, 12, .	1.3	2